Pancreatic cancer is the sixth most common cause of cancer-related death in Europe.
Most common presentation is at 65 to 75 years of age with painless obstructive jaundice and weight loss. Generally presents late with advanced disease.
Surgical resection offers the only hope for cure. Chemotherapy and radiotherapy, as primary treatment modalities, produce a small but statistically significant benefit. Adjuvant chemotherapy prolongs survival.
Only a minority (5% to 10%) of patients can undergo potentially curative surgery: these patients have a 5-year survival of up to 22%, which decreases to <2% in the presence of distant metastasis.
Patients with metastatic disease (50% to 55%) have a limited survival of only 3 to 6 months.
Chemotherapy or immunotherapy may provide some benefit for selected patients.
'Pancreatic cancer' refers to primary pancreatic ductal adenocarcinoma, which accounts for >90% of all pancreatic neoplasms. The course of pancreatic cancer has been shown to follow a linear progression model from pre-invasive pancreatic intraepithelial neoplastic lesions to invasive ductal adenocarcinoma. Two additional well-defined precursor lesions are the intraductal papillary mucinous neoplasm and the mucinous cystic neoplasm.
For diagnosis and management of neuroendocrine tumours of the pancreas, see VIPoma.
History and exam
Key diagnostic factors
- presence of risk factors
- non-specific upper abdominal pain or discomfort
- weight loss and anorexia
- back pain
Other diagnostic factors
- age 65 to 75 years
- thirst, polyuria, nocturia, and weight loss
- nausea, vomiting, and early satiety
- unexplained acute pancreatitis
- epigastric abdominal mass
- positive Courvoisier's sign
- petechiae, purpura, bruising
- Trousseau's sign (migratory thrombophlebitis)
- family history of pancreatic cancer
- other hereditary cancer syndromes
- chronic sporadic pancreatitis
- diabetes mellitus
- dietary factors
1st investigations to order
- pancreatic protocol CT
- abdominal ultrasound
Investigations to consider
- prothrombin time (PT)
- cancer antigen (CA)19-9 biomarker
- positron emission tomography
- endoscopic retrograde cholangiopancreatography (ERCP)
- MRI abdomen
- magnetic resonance cholangiopancreatography
- endoscopic ultrasound
- staging laparoscopy (with laparoscopic ultrasound)
- genomic testing
resectable (stages I and II)
locally advanced unresectable (stage III)
metastatic (stage IV)
- Chronic pancreatitis
- Bile duct stones
- Ampullary carcinoma
- Informed consent for GI endoscopic procedures
- NCCN clinical practice guidelines in oncology: pancreatic adenocarcinoma
Pancreas cancer: questions to ask your doctorMore Patient leaflets
- Log in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer